

17 April 2023

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

Successful leach testing of PFAS media

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, is pleased to announce recent results from the leach testing of its proprietary per-fluoroalkyl and poly-fluoroalkyl compounds ("PFAS") remediation media to EPA-proposed drinking water regulations.

The United States Environment Protection Agency ("EPA") analysis method, EPA SW-864-1311, confirmed that once the media had been contaminated with PFAS, the captured PFAS remains permanently in the media eliminating the risk of PFAS leaching back into the water stream or the environment. This unique capability is especially important in solving the problem of safely disposing of PFAS-contaminated media which is a significant component of the overall cost of PFAS remediation. Existing disposal options are costly or have environmentally damaging drawbacks. The ability of the Company's media to capture and immobilize EPA-targeted PFAS chemicals within drinking water enables safe and sustainable disposal of PFAS-contaminated material to solids waste landfills without the risk of re-contaminating water streams or the environment.

Background on the Test

Specialized laboratories holding accreditation for PFAS in drinking water conduct the test and provide the analytical data confirming whether the PFAS-laden filter media is leaching any of the EPA-proposed National Primary Drinking Water Regulation PFAS family chemicals: PFOA, PFOS, PFHxS, PFNA, PFBS and GenX. EPA Method SW-846 1311, Toxicity Characterization Leaching Procedure (TCLP) test determines the mobility of organic and inorganic contaminants in potentially hazardous waste. The leaching process simulates conditions present in a landfill as liquids percolate through the solid waste.

PFAS, which stands for per-fluoroalkyl and poly-fluoroalkyl compounds, are a collection of long-lasting manmade toxic chemicals, which present a threat to the environment and human health.

Connie Mixon, CEO, commented:

"This is a positive step forward for our patented PFAS remediation offering, as it confirms that we no longer need to incinerate our contaminated media, once the PFAS removal process has been undertaken. The ability to store in landfill rather than incinerate has multiple benefits to potential customers, primarily on cost and environmental grounds.

We continue to believe that PFAS remediation will be a global growth market and we remain excited about becoming a leading player in the sector. I look forward to updating all our stakeholders on further developments with our PFAS offering over the coming months."

For further information, please contact:

MYCELX Technologies Corporation

Connie Mixon, CEO
Kim Slayton, CFO

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor
Gordon Hamilton

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme
Jimmy Lea

Tel: +44 20 8434 2754

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAKZGMDFVMGFZM